1. Home
  2. VTEX vs GERN Comparison

VTEX vs GERN Comparison

Compare VTEX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTEX
  • GERN
  • Stock Information
  • Founded
  • VTEX 1999
  • GERN 1990
  • Country
  • VTEX Cayman Islands
  • GERN United States
  • Employees
  • VTEX N/A
  • GERN N/A
  • Industry
  • VTEX Computer Software: Prepackaged Software
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • VTEX Technology
  • GERN Health Care
  • Exchange
  • VTEX Nasdaq
  • GERN Nasdaq
  • Market Cap
  • VTEX 1.2B
  • GERN 974.5M
  • IPO Year
  • VTEX 2021
  • GERN 1996
  • Fundamental
  • Price
  • VTEX $6.29
  • GERN $1.26
  • Analyst Decision
  • VTEX Strong Buy
  • GERN Buy
  • Analyst Count
  • VTEX 4
  • GERN 8
  • Target Price
  • VTEX $8.70
  • GERN $3.71
  • AVG Volume (30 Days)
  • VTEX 1.4M
  • GERN 8.9M
  • Earning Date
  • VTEX 08-07-2025
  • GERN 08-07-2025
  • Dividend Yield
  • VTEX N/A
  • GERN N/A
  • EPS Growth
  • VTEX N/A
  • GERN N/A
  • EPS
  • VTEX 0.07
  • GERN N/A
  • Revenue
  • VTEX $228,237,000.00
  • GERN $116,293,000.00
  • Revenue This Year
  • VTEX $11.98
  • GERN $161.44
  • Revenue Next Year
  • VTEX $16.19
  • GERN $53.06
  • P/E Ratio
  • VTEX $88.58
  • GERN N/A
  • Revenue Growth
  • VTEX 7.72
  • GERN 22264.04
  • 52 Week Low
  • VTEX $4.20
  • GERN $1.17
  • 52 Week High
  • VTEX $8.03
  • GERN $4.89
  • Technical
  • Relative Strength Index (RSI)
  • VTEX 47.68
  • GERN 41.41
  • Support Level
  • VTEX $6.08
  • GERN $1.20
  • Resistance Level
  • VTEX $6.82
  • GERN $1.37
  • Average True Range (ATR)
  • VTEX 0.23
  • GERN 0.08
  • MACD
  • VTEX -0.03
  • GERN -0.00
  • Stochastic Oscillator
  • VTEX 28.38
  • GERN 21.43

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: